---
title: "Single-cell spatial transcriptomic atlas of metastatic breast cancer progression"
id: "medrxiv-17-a-spatial-single-cell-transcriptomic-atlas-of-metastatic-breast-cancer"
canonical_url: "https://medichelpline.com/clinical-feed/medrxiv-17-a-spatial-single-cell-transcriptomic-atlas-of-metastatic-breast-cancer"
content_type: "clinical_feed_article"
specialty: "Oncology"
source_name: "medRxiv (Clinical Preprints)"
source_url: "https://www.medrxiv.org/content/10.64898/2026.09.04.26361940v1?rss=1"
published_at: "2026-09-10T12:00:00.000Z"
evidence_level: "Verified Feed"
license: "CC-BY-NC-4.0 / Informational Use"
---
# Single-cell spatial transcriptomic atlas of metastatic breast cancer progression
## Provenance & Clinical Metadata
- **Canonical URL:** https://medichelpline.com/clinical-feed/medrxiv-17-a-spatial-single-cell-transcriptomic-atlas-of-metastatic-breast-cancer
- **Specialty:** [Oncology](https://medichelpline.com/clinical-feed/oncology.md)
- **Primary Source:** medRxiv (Clinical Preprints)
- **Source URL:** [Original Journal Publication](https://www.medrxiv.org/content/10.64898/2026.09.04.26361940v1?rss=1)
- **Published At:** 2026-09-10T12:00:00.000Z
- **Evidence Rating:** Verified Feed
## Executive GIST (TL;DR)
- The study presents a **single-cell spatial transcriptomics** atlas from 126 tumor samples collected from 44 patients with metastatic breast cancer, generating data for 520,850 cells in total. - The dataset includes 171,766 **cancer cells** and 349,084 cells from the **tumor microenvironment**, sampled from primary and metastatic lesions. - Multiple time points per patient were analyzed for most cases, enabling detection of **treatment-induced transcriptional changes** in tumor cells that are associated with therapy resistance. - Distinct immune cell subpopulations became enriched at progression after specific therapies; these immune changes were **predictive of hormone receptor loss** in tumors. - The authors inferred **DNA copy number alterations (CNAs)** from single-cell transcriptomes to track subclonal selection during progression and to identify transcriptomic characteristics of clones that outcompete others and possess future metastatic potential. - The study emphasizes tumor heterogeneity, tumor–stromal interactions, and clonal selection as key processes in metastasis and progression, providing a spatial framework across a complex systemic treatment landscape. - Raw and processed data are available at the BioImage Archive (S-BIAD2706) and the Single Cell Portal (SCP3851); analysis code is published on GitHub. - Ethical approval was obtained from the local medical ethics committee of the Netherlands Cancer Institute and the Portuguese Oncology Institute of Porto (IRB reference CFMPB411); all patients provided informed consent. - Competing interests: two authors are employed by Xilis B.V., owner of the MOS technology; other authors declared no competing interests.
## Clinical Analysis & Structured Key Points
A spatial single-cell transcriptomic atlas of metastatic breast cancer progression | medRxiv Skip to main content A spatial single-cell transcriptomic atlas of metastatic breast cancer progression View ORCID Profile Zhanna Dauyey , View ORCID Profile Arno Velds , Roán Gobits , Iris de Rink , View ORCID Profile Karianne Schuurman , View ORCID Profile Merel Roest , Isabel Mayayo-Peralta , Suzanne Beerthuijzen , Marcos Da Silva Guimaraes , View ORCID Profile Sten Cornelissen , Joyce Sanders , View ORCID Profile Marja Nieuwland , View ORCID Profile Iris M. Seignette , Francesca Paolucci , J. Christoph Lampert , Carmen Jeronimo , View ORCID Profile Rui Henrique , View ORCID Profile Roderick Beijersbergen , View ORCID Profile Sebastian Gregoricchio , View ORCID Profile Wilbert Zwart doi: https://doi.org/10.64898/2026.09.04.26361940 Zhanna Dauyey 1 Division of Oncogenomics, Oncode Institute, Netherlands Cancer Institute, Amsterdam, The Netherlands; Find this author on Google Scholar Find this author on PubMed Search for this author on this site ORCID record for Zhanna Dauyey Arno Velds 2 Genomics Core Facility, Netherlands Cancer Institute, Amsterdam, The Netherlands; Find this author on Google Scholar Find this author on PubMed Search for this author on this site ORCID record for Arno Velds Roán Gobits 1 Division of Oncogenomics, Oncode Institute, Netherlands Cancer Institute, Amsterdam, The Netherlands; Find this author on Google Scholar Find this author on PubMed Search for this author on this site Iris de Rink 2 Genomics Core Facility, Netherlands Cancer Institute, Amsterdam, The Netherlands; Find this author on Google Scholar Find this author on PubMed Search for this author on this site Karianne Schuurman 1 Division of Oncogenomics, Oncode Institute, Netherlands Cancer Institute, Amsterdam, The Netherlands; Find this author on Google Scholar Find this author on PubMed Search for this author on this site ORCID record for Karianne Schuurman Merel Roest 1 Division of Oncogenomics, Oncode Institute, Netherlands Cancer Institute, Amsterdam, The Netherlands; Find this author on Google Scholar Find this author on PubMed Search for this author on this site ORCID record for Merel Roest Isabel Mayayo-Peralta 1 Division of Oncogenomics, Oncode Institute, Netherlands Cancer Institute, Amsterdam, The Netherlands; Find this author on Google Scholar Find this author on PubMed Search for this author on this site Suzanne Beerthuijzen 1 Division of Oncogenomics, Oncode Institute, Netherlands Cancer Institute, Amsterdam, The Netherlands; Find this author on Google Scholar Find this author on PubMed Search for this author on this site Marcos Da Silva Guimaraes 3 Department of Pathology, Netherlands Cancer Institute, Amsterdam, The Netherlands; Find this author on Google Scholar Find this author on PubMed Search for this author on this site Sten Cornelissen 4 Core Facility Molecular Pathology, Netherlands Cancer Institute, Amsterdam, The Netherlands; Find this author on Google Scholar Find this author on PubMed Search for this author on this site ORCID record for Sten Cornelissen Joyce Sanders 3 Department of Pathology, Netherlands Cancer Institute, Amsterdam, The Netherlands; Find this author on Google Scholar Find this author on PubMed Search for this author on this site Marja Nieuwland 2 Genomics Core Facility, Netherlands Cancer Institute, Amsterdam, The Netherlands; Find this author on Google Scholar Find this author on PubMed Search for this author on this site ORCID record for Marja Nieuwland Iris M. Seignette 3 Department of Pathology, Netherlands Cancer Institute, Amsterdam, The Netherlands; Find this author on Google Scholar Find this author on PubMed Search for this author on this site ORCID record for Iris M. Seignette Francesca Paolucci 5 Xilis B.V., Universiteitsweg 101, 3584 CG Utrecht, The Netherlands; Find this author on Google Scholar Find this author on PubMed Search for this author on this site J. Christoph Lampert 5 Xilis B.V., Universiteitsweg 101, 3584 CG Utrecht, The Netherlands; Find this author on Google Scholar Find this author on PubMed Search for this author on this site Carmen Jeronimo 6 Cancer Biology & Epigenetics Group, IPO Porto Research Center, Portuguese Oncology Institute of Porto (IPO Porto), Porto, Portugal; Find this author on Google Scholar Find this author on PubMed Search for this author on this site Rui Henrique 6 Cancer Biology & Epigenetics Group, IPO Porto Research Center, Portuguese Oncology Institute of Porto (IPO Porto), Porto, Portugal; Find this author on Google Scholar Find this author on PubMed Search for this author on this site ORCID record for Rui Henrique Roderick Beijersbergen 7 Division of Molecular Carcinogenesis, The NKI Robotics and Screening Center, The Netherlands Cancer Institute, Amsterdam, The Netherlands Find this author on Google Scholar Find this author on PubMed Search for this author on this site ORCID record for Roderick Beijersbergen Sebastian Gregoricchio 1 Division of Oncogenomics, Oncode Institute, Netherlands Cancer Institute, Amsterdam, The Netherlands; Find this author on Google Scholar Find this author on PubMed Search for this author on this site ORCID record for Sebastian Gregoricchio Wilbert Zwart 1 Division of Oncogenomics, Oncode Institute, Netherlands Cancer Institute, Amsterdam, The Netherlands; Find this author on Google Scholar Find this author on PubMed Search for this author on this site ORCID record for Wilbert Zwart For correspondence: w.zwart{at}nki.nl Abstract Info/History Metrics Data/Code Preview PDF Abstract Metastatic breast cancer represents a major societal burden and is a main cause of cancer-related death in women, with limited rationale-based treatment options and often dismal outcomes. Intra-tumor heterogeneity, tumor-stromal interactions and clonal selection are considered to play a major role in metastasis formation and disease progression, but these processes remain incompletely understood. Leveraging spatial transcriptomics as cost-effective method for generating transcriptomics data at single-cell resolution, we present a single-cell spatial transcriptomics atlas of 126 tumor samples from 44 metastatic breast cancer patients, encompassing 520,850 cells from primary and metastatic lesions, with 171,766 cancer cells and 349,084 cells belonging to the tumor microenvironment. For most patients, multiple time-points of sample collection throughout metastatic disease progression were analyzed, allowing for detection of treatment-induced transcriptional changes driving therapy resistance within the tumor cell compartment. Distinct immune cell subpopulations were enriched upon progression following specific therapeutics and were predictive for hormone receptor loss. By inferring DNA copy number alterations from the single-cell transcriptomics data, we tracked subclonal tumor cell selection upon progression and identified critical transcriptomic features of outcompeting clones with future metastatic potential. Cumulatively, we present a unique single-cell spatial framework on metastatic breast cancer development and progression, in a highly complex systemic treatment landscape. Competing Interest Statement Francesca Paolucci and J. Christoph Lampert are employed by Xilis B.V. which owns the MOS technology. The other authors declare no competing interests. Author Declarations I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained. Yes The details of the IRB/oversight body that provided approval or exemption for the research described are given below: This study was approved by the local medical ethics committee of the Netherlands Cancer Institute and Portuguese Oncology Institute of Porto (Institutional Review Board (IRB) reference number: CFMPB411) and complies with the ethical principles of the Declaration of Helsinki. All patients provided informed consent for translational studies. I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals. Yes I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance). Yes I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable. Yes Data Availability Raw and analyzed single-cell spatial transcriptomics and spectral flow cytometry data are available at the BioImage Archive under accession number S-BIAD2706. The data can also be explored at the Single Cell Portal under accession number SCP3851. All the codes used for the analyses presented in this manuscript are available on GitHub at https://github.com/sebastian-gregoricchio/Dauyey_Velds__BRCa_single_cell_transcriptomic_atlas_CODES. https://www.ebi.ac.uk/biostudies/bioimages/studies/S-BIAD2706 https://singlecell.broadinstitute.org/single_cell/reviewer_access/7ea63c58-e239-433c-9fa0-283848f9ff4f https://github.com/sebastian-gregoricchio/Dauyey_Velds__BRCa_single_cell_transcriptomic_atlas_CODES Funder Information Declared Dutch Cancer Society, https://ror.org/0368jnd28 Ministry of Health Welfare and Sport, https://ror.org/041evnj42 European Union’s Horizon 2020 research and innovation programme , 101034290 (EMERALD International PhD Programme for Medical Doctors) Health Holland Copyright The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license . Back to top Previous Posted September 10, 2026. Download PDF Data/Code Email Thank you for your interest in spreading the word about medRxiv. NOTE: Your email address is requested solely to identify you as the sender of this article. Your Email * Your Name * Send To * Enter multiple addresses on separate lines or separate them with commas. You are going to email the following A spatial single-cell transcriptomic atlas of metastatic breast cancer progression Message Subject (Your Name) has forwarded a page to you from medRxiv Message Body (Your Name) thought you would like to see this page from the medRxiv website. Your Personal Message CAPTCHA This question is for testing whether or not you are a human visitor and to prevent automated spam submissions. Share A spatial single-cell transcriptomic atlas of metastatic breast cancer progression Zhanna Dauyey , Arno Velds , Roán Gobits , Iris de Rink , Karianne Schuurman , Merel Roest , Isabel Mayayo-Peralta , Suzanne Beerthuijzen , Marcos Da Silva Guimaraes , Sten Cornelissen , Joyce Sanders , Marja Nieuwland , Iris M. Seignette , Francesca Paolucci , J. Christoph Lampert , Carmen Jeronimo , Rui Henrique , Roderick Beijersbergen , Sebastian Gregoricchio , Wilbert Zwart medRxiv 2026.09.04.26361940; doi: https://doi.org/10.64898/2026.09.04.26361940 Share This Article: Copy Citation Tools A spatial single-cell transcriptomic atlas of metastatic breast cancer progression Zhanna Dauyey , Arno Velds , Roán Gobits , Iris de Rink , Karianne Schuurman , Merel Roest , Isabel Mayayo-Peralta , Suzanne Beerthuijzen , Marcos Da Silva Guimaraes , Sten Cornelissen , Joyce Sanders , Marja Nieuwland , Iris M. Seignette , Francesca Paolucci , J. Christoph Lampert , Carmen Jeronimo , Rui Henrique , Roderick Beijersbergen , Sebastian Gregoricchio , Wilbert Zwart medRxiv 2026.09.04.26361940; doi: https://doi.org/10.64898/2026.09.04.26361940 Citation Manager Formats BibTeX Bookends EasyBib EndNote (tagged) EndNote 8 (xml) Medlars Mendeley Papers RefWorks Tagged Ref Manager RIS Zotero Tweet Widget Facebook Like Google Plus One Subject Area Oncology Subject Areas All Articles Addiction Medicine (616) Allergy and Immunology (898) Anesthesia (330) Cardiovascular Medicine (4796) Dentistry and Oral Medicine (478) Dermatology (414) Emergency Medicine (647) Endocrinology (including Diabetes Mellitus and Metabolic Disease) (1624) Epidemiology (15909) Forensic Medicine (32) Gastroenterology (1200) Genetic and Genomic Medicine (7028) Geriatric Medicine (732) Health Economics (1063) Health Informatics (5026) Health Policy (1431) Health Systems and Quality Improvement (1754) Hematology (584) HIV/AIDS (1341) Infectious Diseases (except HIV/AIDS) (16275) Intensive Care and Critical Care Medicine (1168) Medical Education (667) Medical Ethics (153) Nephrology (722) Neurology (7245) Nursing (366) Nutrition (1078) Obstetrics and Gynecology (1237) Occupational and Environmental Health (1003) Oncology (3596) Ophthalmology (1047) Orthopedics (397) Otolaryngology (451) Pain Medicine (469) Palliative Medicine (139) Pathology (706) Pediatrics (1792) Pharmacology and Therapeutics (735) Primary Care Research (762) Psychiatry and Clinical Psychology (5875) Public and Global Health (9737) Radiology and Imaging (2408) Rehabilitation Medicine and Physical Therapy (1446) Respiratory Medicine (1246) Rheumatology (639) Sexual and Reproductive Health (770) Sports Medicine (578) Surgery (774) Toxicology (107) Transplantation (304) Urology (289)
## Related Clinical Research

- [Inflammatory Biomarkers and Risk of Postmenopausal ER-Positive Breast Cancer](https://medichelpline.com/clinical-feed/british-journal-of-cancer-0-inflammatory-biomarkers-and-risk-of-postmenopausal-oestrogen-receptor-positive.md)
- [Educating Patients on ‘Asian Glow’ and Alcohol Risks in East Asian Populations](https://medichelpline.com/clinical-feed/stat-news-0-opinion-doctors-should-educate-patients-about-asian-glow-and-drinking-risks.md)
- [Federated Learning and In-House Dashboards for Data Quality Assurance in Multi‑Center Oncology Data](https://medichelpline.com/clinical-feed/medrxiv-14-data-auditing-and-quality-assurance-in-a-federated-learning-consortium-getting.md)
- [Sellas Phase 3 REGAL trial for galinpepimut-S faces delays and likely negative outcome in AML](https://medichelpline.com/clinical-feed/stat-news-1-stat-a-sellas-immunotherapy-study-long-delayed-will-end-in-failure.md)
- [Healthy lifestyle and pan-cancer risk: UK Biobank prospective analysis](https://medichelpline.com/clinical-feed/british-journal-of-cancer-2-healthy-lifestyle-and-cancer-risk-a-pan-cancer-analysis-in-the-uk-biobank.md)

## Navigation
- [← Back to Oncology Feed](https://medichelpline.com/clinical-feed/oncology.md)
- [← All Clinical Specialties](https://medichelpline.com/clinical-feed.md)
## Medical & Regulatory Disclaimer

> [!CAUTION]
> MedicHelpline content is structured for research, educational, and professional discovery purposes. It does not constitute individual medical advice, clinical diagnosis, or treatment recommendations.
> Always verify dosing, contraindications, and regulatory alerts against official product labeling and primary regulatory sources before clinical decision-making.